Life Cycle Management Strategies Study 2015 - Optimizing Revenues and Defending Generic Competition
DUBLIN, Aug. 18, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/5k9lkv/life_cycle) has announced the addition of the "Life Cycle Management Strategies - Optimizing Revenues and Defending Generic Competition" report to their offering.
This report, ""Life Cycle Management Strategies - Optimizing revenues and defending generic competition"" discusses various stages of product lifecycle management (LCM), Developmental, commercial and legal LCM strategies, objectives, benefits, factors impacting the choice of lifecycle management strategies, and keys to successful implementation of the strategies. The report provides detailed case studies for each of the key strategies such as indication expansion, reformulation, fixed-dose combinations, pricing strategies and so on.
Scope of the report:
- Introduction of LCM and product life cycle - Objectives of LCM and factors impacting the choice of strategies - LCM strategies depending on the way of approach - Impact of LCM strategies on sales and growth trend of selected products - Patent term extension and market exclusivity in the US and Europe - LCM strategies of pipeline drugs of key players - Keys to successful implementation of LCM strategies
Key Reasons to Purchase:
- Identify the key LCM strategies used by most of the pharmaceutical companies - Analyze the strategies to increase lifecycle and revenues of a drug - Gain an understanding on the implementation of multiple strategies for a single product by including case studies - Understand the operational pipeline strategies of key players
Key Topics Covered:
1. Executive Summary
2. Introduction
2.1 Overview of Product Life Cycle
2.2 Product Life Cycle Curve
2.3 Objectives of Life Cycle Management (LCM)
2.4 Classification and Benefits of LCM Strategies
3. Strategic Planning for LCM 3.1 Factors Impacting Choice of LCM Strategies 3.2 Developmental Strategies 3.3 Indication Expansion/Sequencing and Repositioning 3.4 Patient Subpopulations and Personalized Medicine 3.5 Reformulation 3.6 New Dosage Forms 3.7 New Route of Administration 3.8 Special Cases
4. New Dosage Strengths and Regimen
4.1 Fixed-Dose Combination and Co-packaging
4.2 Next Generation Products and Modified Chemistry
4.3 Metabolites
4.4 Chiral Switching
4.5 Polymorphs
4.6 Multiple Developmental Strategy Approach
5. Commercial Strategies 5.1 Rx-to-OTC/BTC Switch 5.2 Geographical Expansion 5.3 Pricing Strategy and Tactics 5.4 Pricing Strategy for Targeting Multiple Indications 5.5 Coupons 5.6 Co-pay Cards 5.7 Awareness, Brand Loyalty and Service Programs
6. Regulatory and Legal Strategies
6.1 Authorized Generics
6.2 Legal Defense and Pay for Delay
6.3 Citizen's Petition
6.4 Patent Term Extension and Market Exclusivity
6.5 The Pharmaceutical Pipeline and LCM
6.6 Successful Implementation of LCM Strategies
7. Appendix
Companies Mentioned
- AbbVie - Actavis - AstraZeneca - Cipla - Gilead - GlaxoSmithKline - Gleevec - Janssen - MannKind - Merck - Novartis - Orexo - Otsuka - Pfizer - Roche - Salix Pharmaceuticals - Sanofi-Aventis - Solvay - Teva - Vifor Pharma
For more information visit http://www.researchandmarkets.com/research/5k9lkv/life_cycle
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Laura Wood, +353-1-481-1716, press@researchandmarkets.net
Share this article